Related Experiment Videos
Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease
Juan Felipe Osorio-Méndez1,2, Ana María Cevallos3
1Laboratorio de Microbiología y Biología Molecular, Programa de Medicina, Corporación Universitaria Empresarial Alexander von Humboldt, Armenia, Colombia.
Abstract:
There is an urgent need to develop new treatments for Chagas' disease. To identify drug targets, it is important to understand the basic biology of Trypanosoma cruzi, in particular with respect to the biological pathways or proteins that are essential for its survival within the host. This review provides a streamlined approach for identifying drug targets using freely available chemogenetic databases and outlines the relevant characteristics of an ideal chemotherapeutic target. Among those are their essentiality, druggability, availability of structural information, and selectivity. At the moment only 16 genes have been found as essential by gene disruption in T. cruzi. At the TDR Targets database, a chemogenomics resource for neglected diseases, information about published structures for these genes was only found for three of these genes, and annotation of validated inhibitors was found in two. These inhibitors have activity against the parasitic stages present in the host. We then analyzed three of the pathways that are considered promising in the search for new targets: (1) Ergosterol biosynthesis, (2) Resistance to oxidative stress, (3) Synthesis of surface glycoconjugates. We have annotated all the genes that participate in them, identified those that are considered as druggable, and incorporated evidence from either Trypanosoma brucei, and Leishmania spp. that supports the hypothesis that these pathways are essential for T. cruzi survival.
Insights
Identifying new Chagas
Area of Science:
- Parasitology and Tropical Diseases
- Drug Discovery and Development
- Molecular Biology and Genetics
Background:
- Chagas' disease, caused by *Trypanosoma cruzi*, lacks effective treatments, necessitating novel therapeutic strategies.
- Understanding essential biological pathways and proteins in *T. cruzi* is crucial for identifying viable drug targets.
- Current drug target identification relies on essentiality, druggability, structural information, and selectivity criteria.
Purpose of the Study:
- To present a streamlined approach for identifying *Trypanosoma cruzi* drug targets using accessible chemogenetic databases.
- To evaluate promising biological pathways—ergosterol biosynthesis, oxidative stress resistance, and glycoconjugate synthesis—for therapeutic intervention.
- To identify druggable genes within these pathways, supported by cross-species evidence from related kinetoplastids.
Main Methods:
- Utilized chemogenetic databases to identify essential genes and druggable targets in *Trypanosoma cruzi*.
- Reviewed published structural information and validated inhibitors for essential genes.
- Analyzed three key metabolic pathways (ergosterol biosynthesis, oxidative stress resistance, glycoconjugate synthesis) for potential drug targets.
Main Results:
- Only 16 essential genes identified in *T. cruzi* via gene disruption.
- Limited structural information and validated inhibitors available for essential genes in public databases.
- Identified druggable genes within the ergosterol biosynthesis, oxidative stress resistance, and glycoconjugate synthesis pathways.
Conclusions:
- The study outlines a systematic method for discovering novel Chagas' disease drug targets.
- Ergosterol biosynthesis, oxidative stress resistance, and glycoconjugate synthesis pathways represent promising avenues for therapeutic development.
- Further research is needed to validate identified targets and develop specific inhibitors for *T. cruzi*.